Identification | Back Directory | [Name]
3-Piperidinol, 4-[[[7-[[(2,7-dimethylimidazo[1,2-a]pyridin-3-yl)methyl]amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]-, (3R,4R)- | [CAS]
2654075-94-0 | [Synonyms]
3-Piperidinol, 4-[[[7-[[(2,7-dimethylimidazo[1,2-a]pyridin-3-yl)methyl]amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]-, (3R,4R)- | [Molecular Formula]
C25H34N8O | [MOL File]
2654075-94-0.mol | [Molecular Weight]
462.59 |
Chemical Properties | Back Directory | [density ]
1.37±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (216.17 mM; Need ultrasonic) | [form ]
Solid | [pka]
14.69±0.40(Predicted) | [color ]
White to light brown |
Hazard Information | Back Directory | [Biological Activity]
CDK7/12-IN-1 is a selective CDK7/12 inhibitor with IC50s of 3 and 277 nM for CDK7 and CDK 12, respectively. CDK7 and CDK12 inhibition is an effective strategy to inhibit tumour growth[1]. | [storage]
Store at -20°C | [References]
[1]. Edward AINSCOW, et al. 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds and their therapeutic use. WO2021122745A1. |
|
|